Paul Gougis, Anne-Sophie Hamy, Floriane Jochum, Kevin Bihan, Marie Carbonnel, Joe-Elie Salem, Elise Dumas, Rayan Kabirian, Beatriz Grandal, Solenn Barraud, Florence Coussy, Judicael Hotton, Raphaelle Savarino, Aurélien Marabelle, Jacques Cadranel, Jean-Philippe Spano, Enora Laas, Fabien Reyal, Baptiste Abbar
IMPORTANCE: With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking. OBJECTIVE: To assess the risk of pregnancy-, fetal-, and/or newborn-related adverse outcomes associated with exposure to ICIs compared with exposure to other anticancer agents. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, all reports mentioning a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical classification group L01) used for a cancer indication registered in the World Health Organization international pharmacovigilance database VigiBase up to June 26, 2022, were extracted...
April 1, 2024: JAMA Network Open